Although recent clinical studies have demonstrated that programed cell death ligand-1 (PD-L1) expression on tumor cells is associated with clinical benefits in the treatment of lung cancer (3, 5), anti ICIs is also effective in some patients whose PD-L1 levels are low in their tumor tissue (2, 4). Here, CD274 is linked to lung cancer.